Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE: GVAX and CRS-207 in metastatic pancreatic cancer
NCT02004262Phase 2Completed
- Sponsor
- Aduro Biotech, Inc.
- Start
- Feb 2014
- Primary completion
- Jan 2016
- Modality
- Oncolytic Viruses, Cell Therapies, Cancer Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of GVAX pancreatic cancer vaccine, CRS-207 in pancreatic adenocarcinoma (PDAC), sponsored by Aduro Biotech, Inc.. Started Feb 2014; status: completed.
02
Drugs
GVAX pancreatic cancer vaccineCRS-207
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02004262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02004262.